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1  Introduction 
 
Mesenchymal stem cells (MSC) are multipotent stem cells from human bone marrow. 
These  MSC,  also  referred  to  as  marrow  stromal  cells,  maintain  the  capacity  to 
differentiate into multiple mesenchymal lineages such as osteoblasts, chondrocytes, 
adipocytes, myoblasts,  stromal, neural and endothelial  cells  (Bianco  et  al. 2001a; 
Tremain et al. 2001; Roufosse et al. 2004). The process of differentiation is regulated 
by intrinsic growth factors and extrinsic signals (Long et al. 1995; Quesenberry et al. 
2002; Moreau et al. 2006). 
The use of autologous MSC has generated considerable interest on account of their 
developing  use  in  regenerative  medicine  and  tissue  engineering  in  orthopedic 
surgery, which has been illustrated in numerous promising pre-clinical and clinical 
trials (Bruder et al. 1998a; Barry & Murphy 2004; DeRubeis & Cancedda 2004). 
Cell  transplantations  date  back  to  the  sixteenth  century  when  the  Italian  surgeon 
Gaspare Tagliacozzi, detailed in his work “De curatorum chirurgica per institionem”, 
attached  a  skin  flap  from  a  patient’s  forearm  to  the  nose  and  released  the  arm 
several weeks later, allowing the skin graft to heal on the nose (Romero-y-Huesca et 
al. 2005; Soto-Miranda et al. 2006). Currently such a procedure, considered a free 
flap transfer, is routinely performed successfully in reconstructive surgery (Bozikov & 
Arnez  2006).  It  is  an  example  of  autologous  grafting,  a  method  using  a  cell 
population to repair a defect at a different anatomical location of the same individual. 
Initiated by complications and limitations of autologous grafting, tissue engineering 
has emerged as a viable alternative. In short, functional tissue is generated in vitro 
using endogenous cells and a synthetic matrix for cellular delivery. 
MSC  are  among  the  cells  necessary  for  successful  implementation  of  such 
applications.  Little  information  is  currently  available  concerning  the  donor 
characteristics for tissue engineering growth of skeletal tissue. As new methods are 
developed, there are several aspects regarding donor gender, age, injury pattern and 
regulatory factors which need to be explored. 
   6
1.1  Marrow stromal cells 
Almost 140 years ago, the German pathologist Julius Cohnheim first suggested the 
existence  of  non-hematopoietic,  undifferentiated  cells  in  bone  marrow  (Cohnheim 
1867).  The  development  of  such  “stem”  cells  was  later  described  in  detail  in  the 
pioneering  studies  of  Friedenstein,  Piatetzky-Shapiro  and  Petrakova  (1966).  They 
reported the isolation of bone-forming progenitor cells from rat marrow. These cells, 
originally referred to as colony forming units-fibroblasts (CFU-F), retained the ability 
for bone and cartilage formation following successive passaging of single-colony and 
multicolonies.  In  addition,  the  content  of  osteogenic  precursors  in  the  cultured 
progeny  significantly  outnumbered  the  initiating  CFU-F,  establishing  their  highly 
proliferative and stem cell-like properties (Friedenstein et al. 1987). Finally named 
mesenchymal stem cells (Caplan 1991), proof of their actual stem cell nature was 
established in the diligent works of Pittenger et al. (1999) and later by Halleux et al. 
(2001).  Direct  experimental  evidence  was  finally  provided  that  cultures  of  bone 
marrow derived mesenchymal cells contain individual cells which possess extensive 
self-renewal capacity and multilineage potential. 
 
In  current  literature,  not  only  can  a  variety  of  nomenclature be found  referring  to 
marrow  stromal  cells  (mesenchymal  stem  cells,  mesenchymal  precursor  cells, 
autologous  progenitor  cells)  but  the  methods  of  isolation,  expansion  and 
characterization differ as well. To address the resulting difficulty in comparing various 
research  outcomes,  the  Mesenchymal  and  Tissue  Stem  Cell  Committee  of  the 
International Society for Cellular Therapy proposed minimal criteria to define human 
MSC.  First,  MSC  must  be  plastic-adherent  when  maintained  in  standard  culture 
conditions. Second, MSC must express CD73, CD90, CD105 and lack expression of 
CD11b, CD14, CD19, CD34, CD45 or CD79-α and HLA-DR surface molecules. Third, 
MSC  must  differentiate  into  osteoblasts,  adipocytes  and  chondroblasts  in  vitro 
(Dominici et al. 2006). Although this definition certainly may be modified in the future, 
it  does  present  guidelines  by  which  the  multiple  parameters  of  MSC  can  be 
characterized and compared. 
 
MSC are generally isolated from an aspirate of adult bone marrow harvested from 
the superior iliac crest of the pelvis, although various mesenchymal tissue sources 
have  been  identified.  Such  alternative  sources  include  tibial  and  femoral  marrow   7
compartments (Murphy et al. 2002; Ciapetti et al. 2006), thoracic and lumbar spine 
(D’Ippolito et al. 1999), adipose tissue (DeUgarte et al. 2003), synovium (DeBari et al. 
2003)  and  skeletal  muscle  (Jankowski  et  al.  2002)  as  well  as  umbilical  cord  and 
embryonic tissue (Erices et al. 2000; Campagnoli et al. 2001). There is support for 
the existence of MSC circulating in blood, although only a small population has been 
identified (Huss et al. 2000; Zvaifler et al. 2000; Kuznetsov et al. 2001; He et al. 
2006;  Khosla  et  al.  2006).  However,  MSC  can  be  routinely  harvested  easily, 
efficiently and in large numbers from adult marrow, also eliminating ethical issues 
inherent in using embryonic or fetal cells. The frequency of MSC residing within the 
stromal compartment of bone marrow is 0.001-0.01% of nucleated cells (Pittenger et 
al. 1999). These typically fusiform cells can be expanded in culture through many 
generations  while  retaining  the  capacity  to  differentiate  (Pittenger  et  al.  1999; 
Majumdar 2000). Following isolation, they are initially fractioned by a density gradient 
and plated. During the period of primary culture, the nonadherent hematopoietic cell 
fraction is depleted while the remaining adherent MSC population forms colonies can 
be further expanded. Their multilineage differentiation potential has been described 
and characterized by multiple laboratories. Under defined culture conditions, they can 
differentiate into osteoblasts, chondrocytes, adipocytes, myoblasts and stromal cells 
as well as nonmesenchymal lineages unrelated to the cells in their tissue of origin 
such  as  neural  cells  and  endothelial  cells,  a  demonstration  of  the  transgermal 
plasticity of MSC (Sanchez-Ramos et al. 2000; Bianco et al. 2001a; Tremain et al. 
2001; Roufosse et al. 2004). 
 
The  manifold  attributes  of  MSC  have  been  extensively  analyzed.  They  can  for 
example  be  functionally  characterized  by  their  osteogenic  differentiation.  In  the 
presence of β-glycerol-phosphate, ascorbic acid-2-phosphate and dexamethasone, 
cells  acquire  an  osteoblastic  morphology  with  upregulation  of  alkaline  phosphate 
(ALP)  activity  and  deposition  of  a  calcium-rich  mineralized  extracellular  matrix 
(Bruder et al. 1997a; Jaiswal et al. 1997). Using established techniques such as flow 
cytometry, MSC show heterogeneous surface markers and have variable potential 
for  mesenchymal  tissue  development.  Numerous  investigations  have  been 
conducted not only to identify markers of mesenchymal and bone progenitors (Bruder 
et  al.  1994;  Barry  et  al.  1999),  but  also  to  address  further  issues  regarding  their 
heterogeneous  properties.  Castro-Malaspina  et  al.  (1980)  demonstrated  in  their   8
pioneering investigations the accurate determination of expansion limitations of MSC 
in culture for large numbers of cells, which has been confirmed in further studies 
(Bruder et al. 1997a; Wexler et al. 2003). However, the proliferative capacity declines 
with repetitive passaging (Caplan et al. 1997; Jaiswal et al. 1997). 
The homing mechanism, a further attribute demonstrated by MSC, has also been 
investigated, whereby systemic or local delivery of MSC results in specific migration 
not only to bone marrow, but also to the site of injury (Pereira et al. 1995; Prockop 
1997). In an animal model, marked MSC were shown to colonize rejected cardiac 
transplant tissue following intravenous injection (Wu et al. 2003). Murphy et al. (2003) 
demonstrated  similar  results  in  a  human  study  where  MSC  delivered  through  an 
intraarticular injection to the knee joint after traumatic injury exhibited the capability of 
engraftment  and  repair  of  damaged  meniscus  and  cartilage.  Further  compelling 
studies evaluated female allograft hearts transplanted into male patients, using the Y 
chromosome  to  detect  migrated  undifferentiated  cells  and  differentiate  between 
donor  and  recipient  origin.  Laflamme  et  al.  (2002)  and  Quaini  et  al.  (2002) 
demonstrated  the  translocation  of  undifferentiated  cells  and  their  repopulation  of 
damaged  myocardial  tissue.  In  addition  to  cells  originating  from  the  donor,  the 
presence of Y chromosome-positive cells confirms the capacity of such extracardiac 
progenitor cells to migrate to sites of tissue injury. 
 
1.2  Factors influencing MSC 
Numerous factors appear to influence the reservoir and proliferative capacity of MSC 
in bone marrow. Age is one factor which has generated considerable investigation. 
The concentration of MSC in bone marrow has been shown in many studies to be 
age-related. Many investigators suggest a decrease with age (D’Ippolito et al. 1999; 
Chen 2004; Abdallah et al. 2006; Mareschi et al. 2006) which would coincide with 
established knowledge of skeletal maturation and degeneration, while others found 
no  change  (Stenderup  et  al.  2001;  Justesen  et  al.  2002).  As  with  age,  there  is 
evidence  that  the  MSC  frequency  in  bone  marrow  is  also  gender-dependent.  In 
women, CFU expressing ALP obtained from bone marrow aspirate was decreased 
(Muschler et al. 2001) as well as the cortical bone mass in postmenopausal women 
(Brockstedt et al. 1993). 
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Furthermore,  investigators  have  identified  interesting  mediators  influencing 
progenitor cell mobilization in trauma situations. Elevated concentrations of VEGF 
and  TGF-β  in  serum  derived  from  multiple  trauma  patients  have  been  shown  to 
promote differentiation of endothelial progenitor cells (Henrich et al. 2004). Hormones, 
growth factors and cytokines are likewise involved in MSC proliferation. Numerous 
influential factors have been discussed, including growth factors (Moreau et al. 2006), 
estrogen and testosterone (DiSilvio et al. 2006), prolactin (Ogueta et al. 2002) and 
interleukins (Strecker et al. 2003). 
 
1.3  Therapeutic applications and relevance in orthopaedic surgery 
The therapeutic value of stem cells is well documented in numerous medical fields 
and has been applied over 40 years. Following the identification of human leukocyte 
antigens (HLA) by the French medical researcher Jean Dausset, the first successful 
bone marrow transplantation was reported by Gatti et al. in 1968 in Minneapolis, MN 
(Gatti et al. 1968; Fischer 1999). Since then, stem cell therapy, in which autologous 
or allogenic undifferentiated stem cells are either locally or systemically delivered and 
ultimately differentiate to the appropriate phenotype under local signals, has provided 
a treatment alternative for many diseases and organ dysfunctions (Meyer et al. 2006). 
In this context, MSC can also be therapeutically applied systematically or with site-
specific delivery vehicles to repair various tissues damaged by disease or trauma 
(Caplan 2005). An abundance of diseases have been targeted for potential MSC use, 
including diabetes mellitus (Lee RH et al. 2006), myocardial infarction (Orlic et al. 
2003), stroke (Li et al. 2005), Parkinson’s disease (Ye et al. 2006) and muscular 
dystrophy (DeBari et al. 2003). Although much of this research is still focused on 
animal models, preliminary results are promising. 
 
Orthopaedic surgery encompasses a wide spectrum of musculoskeletal conditions 
from  acute  injury  to  disease  to  congenital  deformities.  Many  challenges  are 
encountered in the treatment of multiple traumas, delayed wound healing, atrophic 
nonunions or increasingly common degenerative diseases such as osteoporosis. The 
Center  for  Disease  Control  in  the  U.S.  reported  an  average  of  1,028,600 
hospitalizations due to fractures per year for 2002-2004 (National Center for Health 
Statistics 2006), 1.5 million of the fractures due to osteoporosis (Orsini et al. 2005) 
and 110,000 patients suffer nonhealing long bone defects (Ringe et al. 2002). Each   10 
year  in  the  U.S.  450,000  bone  grafts  are  performed  following  various  indications 
(Service  2000).  Further  demands  result  from  the  continuously  growing  elderly 
population. In a report focusing on adults older than 65 years, fractures were the 
most frequent and expensive type of injury in 2000, accounting for 35% of non-fatal 
injuries and 61% of direct medical costs which totaled $19 billion. Additionally, the 
incidence of fall injuries for women was 2.3 times higher and the medical cost 2.8 
times higher than for men (Stevens & Sogolo 2005; Stevens et al. 2006). In Germany 
alone,  1.5  million  people  with  degenerative  joint  diseases  are  under  medical 
treatment (Ringe et al. 2002). Considering the demographics, incidence and costs of 
skeletal injury and disease, development of safe and more effective functional tissue 
replacement becomes increasingly necessary. 
 
Osteogenic cells are a prerequisite for such methods of bone reconstruction. MSC 
have  successfully  been  implemented  for  generation  of  replacement  tissue  for 
orthopedic procedures in numerous studies (Gao & Caplan 2003; Niemeyer et al. 
2004b). The benefit of  MSC  use  in many  orthopedic  surgery  situations  has  been 
recently documented, such as segmental bone defects (Quarto et al. 2001), cartilage 
(Wakitani et al. 2002), tendon (Ouyang et al. 2004), wound repair (McFarlin et al. 
2006), spinal fusion (Muschler et al. 2005), osteogenesis imperfecta (Horwitz et al. 
2002) and in osteoarthritis (Murphy et al. 2003). Currently, autologous bone grafting 
is often achieved by transferring cancellous bone tissue from the iliac crest of the 
pelvis to the fracture site, providing mechanical stabilization as well as osteogenic 
progenitor cell enrichment. It can be used in fracture treatment, to induce joint fusion 
or  fill  segmental  bone  defects  (Caterson  et  al.  2001).  Such  methods  are  still 
considered standard for osteogenic bone replacement in extended defects (Kneser et 
al. 2006). However, the clinical use of autologous osseous transplants is limited by 
donor site morbidity, increasing with the amount of harvested bone. Bone substitutes 
used in combination with autologous bone grafts can decrease the amount of bone 
tissue  needed  for  reconstruction  (Kneser  et  al.  2006).  Recent  progress  in  the 
isolation and characterization of MSC has led to extensive research in therapeutic 
strategies  in  a  variety  of  orthopaedic  surgery  applications,  including  tissue 
engineering. 
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Tissue engineering is a viable alternative to allogen and autologous grafting in terms 
of reconstructive surgery, as it is associated with fewer limitations such as tissue 
availability,  harvesting  difficulties,  donor  site  morbidity,  immune  reaction  or 
transmission of disease (Schaefer et al. 2000). In tissue engineering procedures, a 
combination of extracellular scaffolds, bioactive factors and patient cells is necessary 
to  generate  functional  replacement  tissue  in  vitro  for  clinical  use  (Schaefer  et  al. 
2000; Caplan & Bruder 2001). Pluripotent MSC in adult tissues have been shown to 
play a significant role in tissue regeneration and homeostasis (Minguell et al. 2001; 
Niemeyer et al. 2004a) and are therefore a promising cell population for such tissue 
engineering  applications.  Many  new  developments  in the management  of  skeletal 
injury  with  osteogenic  progenitor  cells  have  been  reported.  Kuroda  et  al.  (2006) 
recently presented a case in which successful full-thickness cartilage repair in a 31 
year  old  male  was  achieved  by  collage-gel-assisted  transplantation  of  in  vitro 
expanded  autologous  MSC  from  the  iliac  crest.  In  this  way,  tissue  engineering 
advances demonstrate how the body’s own rejuvenative potential can be utilized by 
applying endogenous in vitro expanded reparative MSC (Caplan & Dennis 2006). 
 
2  Aims of this thesis 
To date there have been no studies published addressing the effect of age, gender, 
site  of  harvest  and  injury  severity  on  the  quantity,  quality  and  osteogenic 
differentiation  of  mesenchymal  stromal  cells  in  injury  situations.  The  goals  of  this 
thesis concentrate therefore on the influence of such donor characteristics on MSC 
from trauma patients. MSC concentration in bone marrow will be verified using the 
CFU-F assay. To determine the proliferative capacity of MSC, densitometric analysis 
will be applied. The results of this study can be used to determine the applicability of 
MSC from various patient groups for tissue engineering procedures. 
 
Aim #1: Evaluate the influence of injury pattern on the quantity and quality of MSC in 
trauma patients 
Aim #2: Evaluate the influence of gender and age on the quantity and quality of MSC 
in trauma patients 
Aim #3: Evaluate the influence of other mediatory factors on the quantity and quality 
of MSC in trauma patients   12 
3  Materials and Methods 
 
3.1  Materials 
 
Table 1: Materials 
 
Equipment:   
Centrifuge  Heraeus, Hanau, Germany 
Incubator  Jouan, Winchester, VA, USA 
Laminar airflow work bench  Antares, Hartmannsdorf, Germany 
Microscope  Carl Zeiss, Göttingen, Germany 
Water bath  GFL 1083, Anunak 
Digital camera, Nikon DR Math. and 
Meth. 2 Coolpix 4500 
Nikon, Düsseldorf, Germany 
Refrigerator, +4 to -20° C  Bosch, Stuttgart, Germany 
Freezer, -80° C  Heraeus, Hanau, Germany 
Counting chamber, Neubauer  Optik Labor, Friedrichshofen, Germany 
Vortex MSI Minishaker  Ika Inst., Wilmington, NC, USA 
Transfer pipettes  Hirschmann Laborgeräte, Eberstadt, 
Germany 
Eppendorf pipettes  Eppendorf, Wesseling-Berzdorf, 
Germany 
Star Lab, Ahrensburg, Germany 
Magnetic heating / stirring plate  IKA Labortechnik, Staufen, Germany 
FACScan (Fluorescent activated cell 
sorting) 
Becton-Dickinson, Heidelberg, Germany 
Multi Analyst software  Bio-Rad, Munich, Germany 
Cell Explorer software  BioSciTek, Frankfurt, Germany 
Disposable material:   
Tubes  Greiner Bio-One, Solingen, Germany 
Culture flasks  Sarstedt, Nümbrecht, Germany 
Transfer pipette tips   Costar, Corning, NY, USA 
Eppendorf pipette tips  Star Lab, Ahrensburg, Germany   13 
Syringes  Becton Dickinson, Fraga, Spain 
Blood tubes  Sarstedt, Nümbrecht, Germany 
Falcon tubes  Sarstedt, Nümbrecht, Germany 
Insulin syringes  Becton Dickinson, Madrid, Spain 
Cryovials  Nalge Nunc, Roskilde, Denmark 
Pasteur pipettes  Sarstedt, Nümbrecht, Germany 
Cell culture plates  Nalge Nunc, Roskilde, Denmark 
Kendall monoject iliac aspiration needles  Tyco Healthcare, Neustadt, Germany 
Buffers and solutions:   
Distilled water (Aqua dest.)  Braun, Melsungen, Germany 
Accutase  PAA Laboratories, Pasching, Austria 
Ficoll 1.077 g  Biochrom, Berlin, Germany 
Erythrocyte lysis solution  self-preparation 
Dulbeccos’s Phosphate Buffered Saline 
without Mg
2+ and Ca
2+ (PBS w/o) 
PAA Laboratories, Pasching, Austria 
Fetal Bovine Serum (FBS)  Gibco, Paisley, Scotland 
Culture mediums:   
MesenCult Basal Medium for Human 
Mesenchymal Stem Cells 
StemCell Technologies, Vancouver, 
Canada  
MesenCult Mesenchymal Stem Cell 
Stimulatory Supplements 
StemCell Technologies, Vancouver, 
Canada 
MesenCult Osteogenic Kit  StemCell Technologies, Vancouver, 
Canada 
Chemicals and reagents:   
Diff-Quick  Baxter, Düdingen, Switzerland 
Sigma Fast Alkaline Phosphatase 
Sustrate Tablets Set 
Sigma, St. Louis MO, USA 
Alizarin red dye  Chroma, Fürstenfeldbruck, Germany 
Fast red dye  University Clinic pharmacy 
Türks dye  Merck, Darmstadt, Germany 
5% Silver nitrate solution  self-preparation, see appendix 
5% Sodium thiosulfate solution  self-preparation, see appendix 
β-Mercaptoethanol  Merk, Darmstadt, Germany   14 
Dimethylsulfoxide (DMSO)  Sigma, Heidelberg, Germany 
Ethanol  Merk, Darmstadt, Germany 
Formaldehyde  Sigma-Aldrich, Seelze, Germany 
Antibodies:   
Iso-PE  BD Biosciences, Heidelberg, Germany 
Iso-FITC  BD Biosciences, Heidelberg, Germany 
Iso-PE-Cy5  BD Biosciences, Heidelberg, Germany 
CD 34-FITC  BD Biosciences, Heidelberg, Germany 
CD 45-FITC  BD Biosciences, Heidelberg, Germany 
CD 71-PE-Cy5  BD Biosciences, Heidelberg, Germany 
CD 73-PE  BD Biosciences, Heidelberg, Germany 
CD 90-PE  BD Biosciences, Heidelberg, Germany 
CD 105-FITC  Serotec, Düsseldorf, Germany 
Medications:   
Heparin 10,000 IU/ml  Ratiopharm, Ulm, Germany 
NaCl 0.9% ampulles  Braun, Melsungen, Germany 
Kits for the detection of hormones 
and cytokines: 
 
17β-estradiol, testosterone, prolactin  Bayer Healthcare, Leverkusen, Germany 
Interleukin-6-ELISA  RayBiotech, Hoelzel Diagnostik GmbH, 
Köln, Germany 
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3.2  Experimental subjects 
Trauma patients who were scheduled to undergo operative procedures on the pelvis, 
vertebrae,  tibia  or hip  as  well  as  cancellous  bone autografts for  reconstruction  of 
various bone defects were included in the study. A total of 58 individuals (51 patients 
and 7 healthy volunteers) participated in the study, ranging from 18 to 64 years of 
age. Criteria for exclusion were pathological fractures due to carcinoma, bacterial or 
viral  infections  and  infectious  diseases  including  Hepatitis  A,  B,  C,  CMV 
(cytomegalovirus infection) and HIV (human immune deficiency virus). Patients were 
discharged  from  the  study  if  the  cell  cultures  showed  signs  of  contamination.  5 
samples  obtained  from  patients  were  not  included  in  statistical  analysis  due  to 
insufficient  growth  (see  Results  4.1.2  and  Discussion  5.2).  The  remaining  53 
participants were then divided into 8 groups according to injury pattern, gender and 
age (Table 2). 18 female and 35 male patients were included. The injury pattern was 
determined  as  follows:  the  first  group  (single  fracture)  included  patients  with  1 
isolated,  primarily  treated  fracture;  the  second  group  (multiple  trauma)  included 
polytraumatized patients with an injury severity score (ISS) of 16 or greater; the third 
group (atrophic nonunion) included patients with fractures over 6 months old with 
radiographic signs of insufficient healing. 7 healthy volunteers were included in the 
control group. All participants and the parents or guardians of minors, as well as all 
healthy volunteers were informed of all procedures before signing a consent form. 
The ethics committee of the University Hospital of Frankfurt approved all procedures. 
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Table 2: Participant groups (n=53) 
 
group  injury pattern  gender  age  number of 
patients (n) 
1 
 
single fracture  female  38±23  3 
2 
 
multiple trauma  female  55±18  4 
3 
 
atrophic 
nonunion 
female  42±13  5 
4 
 
healthy 
volunteers 
female  33±6  4 
5 
 
single fracture  male  46±17  11 
6 
 
multiple trauma  male  37±10  9 
7 
 
atrophic 
nonunion 
male  41±15  14 
8 
 
healthy 
volunteers 
male  32±9  3 
 
3.3  Bone marrow extraction 
For the extraction of human marrow stromal cells (MSC), a minimum of 6 ml bone 
marrow  was  aspirated  intraoperatively  under  sterile  conditions.  Depending  on  the 
procedure, the cells were obtained from an aspirate of the iliac crest (n=46), proximal 
extremity of the tibia (n=3), greater trochanter (n=1), vertebral body (n=1) in trauma 
patients or pelvic bone puncture in health volunteers (n=7). 5,000 IU Heparin and 4.5 
ml 0.9% saline solution were added, gently mixed and the sample was immediately 
processed. 
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3.4  Isolation of human marrow stromal cells 
The  following  procedures  for  processing  the  MSC  were  conducted  under  sterile 
conditions.  The  original  volume  of  bone  marrow  was  noted  before  washing  the 
suspension twice with an equal amount of Phosphate Buffered Saline, without Mg
2+ 
and Ca
2+ (PBS w/o). The sample was centrifuged between wash cycles at 850 g for 
10 minutes at room temperature.
 The cells were then separated by density gradient 
centrifugation. Briefly, the cells were resuspended in a volume of PBS w/o equal to 
the original sample and overlaid onto a Ficoll density gradient. The mononuclear cell 
suspension was isolated by centrifugation at 1000 g for 30 min. Following careful 
removal of the cell layer, the cells were washed in PBS w/o containing 2% Fetal 
Bovine  Serum  (FBS),  pelleted  by  centrifugation  at  850  g  for  10  minutes  and 
resuspended in 3 ml MesentCult Basal Medium for Human Mesenchymal Stem Cells 
containing MesenCult Mesenchymal Stem Cell Stimulatory Supplements (450 ml:50 
ml). The contaminating red blood cells were lysed in lysis solution (1:3 v/v) for 5 
minutes before staining the remaining cells with Türks dye. The cells could then be 
accurately counted using a Neubauer counting chamber and seeded in culture flasks. 
See also Protocol 1 and Protocol 2 in the appendix. 
 
3.5  Cultivation and expansion of human marrow stromal cells 
The cells were cultivated in 25 cm
2 culture flasks with 10 ml of MesenCult medium 
plus supplements each at 37° C and 5% CO 2. Adherent cells were allowed to reach 
approximately  30%  confluence  before  the  cultures  were  split  and  passaged.  The 
medium was changed 3 times a week. 3 culture flasks were allocated for the colony 
forming unit-fibroblast (CFU-F) assay, with cells plated at densities of 5 x 10
5, 1 x 10
6 
and 2 x 10
6. Any additional cells were seeded at a density of 2 x 10
6 for further 
analyses. The criterion of 30% confluence is based on a survey conducted parallel to 
standard  cultivation.  To  observe  at  which  confluence  the  cells  could  be  optimally 
passaged, cultures from 5 patients were chosen randomly and 2 culture flasks from 
each patient were cultivated according to procedures described in Protocol 1. The 
cultures were divided into 2 groups: low and high density and passaged after 30% or 
80% confluence respectively until proliferation stagnated. The maximum number of 
proliferative passages could then be observed. 
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3.6  Characterization of human marrow stromal cells 
 
3.6.1  Colony forming unit-fibroblast (CFU-F) assay 
For the CFU-F assay, the culture flask with cells plated at a density of 1 x 10
6 as 
mentioned above were used. The cells were allowed to adhere for 14 days during 
which the medium was changed 3 times a week. On day 14 the cells were stained 
using Diff-Quick. After medium removal, the cells were rinsed with distilled water and 
fixed and stained with the 3 formulas included in the Diff-Quick staining set (methanol, 
buffered  eosin,  buffered  azure).  They  were  rinsed  again  with  distilled  water  and 
allowed to air-dry. Each culture flask was then photographed, digitized and converted 
to an 8 bit grey level TIF-format. See also Protocol 3 in the appendix. 
 
3.6.2  Mean  colony  number,  mean  colony  area,  and  mean  cell  number  per 
microscopic field of view 
Using the digitized CFU-F assay, the mean colony number, mean colony area and 
mean  cell  number  per  microscopic field  of view  (FOV)  could  be determined. The 
software Cell Explorer was used to assess the colony number and mean colony area. 
To establish mean cell number per microscopic FOV the following procedures were 
applied: first, the mean cell number per colony was determined using 15 randomly 
chosen stained colonies from a total of 3 patients. Within each colony, the cells in 4 
peripheral and 1 central randomly chosen area were counted microscopically (100 x 
magnification, FOV 0.1 x 0.1 mm) using an ocular grid and the mean cell density was 
calculated. In a second adjacent step, the colonies processed above were marked, 
photographed and digitally converted into an 8 bit gray level format. The mean gray 
level was then assessed (including background correction) using the software Multi 
Analyst. The mean cell number per FOV from the first step was then plotted against 
the  corresponding  gray  level  from  the  second  step  and  a  calibration  curve  was 
generated. Consequently, the mean cell number per colony could be calculated by 
applying linear regression. 
   19 
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Figure 1: Gray level and mean cell number per FOV (field of view) 
The  mean  cell  density  is  plotted  against  the  mean  gray  level.  By  applying  linear 
regression, the mean cell number per colony can be calculated. 
 
The  mean  cell  number  per  FOV  (cell  density)  correlated  significantly  with  the 
corresponding gray level of the colony (Fig. 1, r=0.92, p<0.00001). Thus, the optical 
CFU-F density reflects the true cell number per colony and represents an appropriate 
surrogate of the proliferative capacity. 
 
3.6.3  Fluorescent activated cell sorting (FACS) 
Data  was  collected  by  analyzing  10,000-50,000  events  and  FACS  analysis  was 
performed  to  characterize  the  surface  antigen  expression  of  CD34,  CD45,  CD71, 
CD73, CD90 and CD105. Cells acquired under identical conditions as above were 
first expanded over 3 passages after a confluence of 30% was attained for each cell 
passage. The cells were detached through incubation with Accutase at 37° C for 10 
minutes,  washed  once  in  PBS  w/o,  centrifuged  at  300  g  for  1  minute  and 
resuspended in PBS w/o containing 0.5% FBS at a concentration of 3 x 10
5 cell/ml. 
100 µl aliquots of the cell suspension were incubated in the refrigerator at 4° C for 20   20 
minutes with 7.5 µl each of the following antibodies: anti-CD34, anti-CD45, anti-CD71, 
anti-CD73, anti-CD90, anti-CD105 and control isotypes. Cells were then washed in 
PBS w/o, suspended in 2 ml 0.5% formaldehyde and incubated for 10 minutes in the 
dark. Finally, the cells were centrifuged at 300 g for 10 minutes and resuspended in 
250  µl  PBS  w/o  for  FACS  analysis.  A  MSC-typical  phenotype  was  required  for 
inclusion of the CFU-F assay in the data. 
 
3.6.4  Staining for osteogenic differentiation 
To determine the potential of MSC for osteogenic differentiation, von Kossa, alkaline 
phosphatase  (ALP)  and  alizarin  staining  was  performed.  Cells  acquired  under 
identical conditions as above were cultivated in 12-well plates at a density of 2 x 10
4 
cells/well  for  2  weeks.  The  osteogenic  differentiation  was  induced  using  the 
MesenCult Osteogenic Kit by supplementation of 42.5 ml MesenCult medium with 
7.5 ml Osteogenic supplements (final volume 15%), 5 µl dexamethasone 10
-4 M (final 
concentration 10
-8 M), 250 µl ascorbic acid 10 mg/ml (final concentration 50 µg/ml) 
and  175  µl  β-glycerophosphate  1.0  M  (final  concentration  3.5  mM).  The  1  ml 
medium/well was changed 3 times a week. On day 14 the calcium deposition was 
verified by the von Kossa staining procedure as follows: first the wells were rinsed 3 
times with distilled water and incubated in 1 ml/well of ice cold ethanol for 20 minutes. 
After rinsing again 3 times with distilled water, the cell cultures were further incubated 
at room temperature in 1 ml/well 5% silver nitrate solution. Following one last rinse 
sequence,  the  un-reacted  silver  was  removed  by  incubation  with  1  ml/well  5% 
sodium thiosulfate and the cells were counterstained with 1 ml/well Fast red dye for 
10 minutes. See also Protocol 4 in the appendix. Alizarin staining for quantification 
of  mineral  deposition  and  ALP  to  verify  osteoblastic  activity  were  both  performed 
using sets according to the instructions of the manufacturer. Subsequently the cells 
were photographed for assessment and documentation. 
 
3.7  Patient serum analysis 
Serum from a total of 39 randomly chosen participants from the 53 patients and 7 
healthy individuals was collected on the day of the operative procedure and levels of 
the  hormones  17β-estradiol,  testosterone,  prolactin  and  the  cytokine  interleukin-6 
were tested as suggested by the manufacturers.   21 
3.8  Statistical analysis 
Values are expressed as a mean ± SD. Statistical analysis was performed using the 
non-parametric  Kruskal  Wallis  test  with  Dunn-posthoc  analysis  with  Holm’s  alpha 
correction for multiplicity. At most four groups were compared against each other, for 
example healthy male volunteers versus male patients with nonunions versus male 
patients with single fractures versus male patients with multiple traumas. A p value 
less than 0.05 was considered significant. Correction analysis was performed using 
the  Spearman-rang  test.  SPSS  V9.0  (SPSS,  Chicago,  IL,  USA)  was  used  for  all 
statistical analysis. 
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4  Results 
 
4.1  Characterization of human marrow stromal cells 
 
4.1.1  Culture passaging at low and high density confluence 
In order to obtain the highest possible number of MSC colonies and optimize the 
yield  of  cultivated  MSC,  the  maximum  number  of  proliferative  passages  was 
evaluated using 10 cultures from 5 different patients passaged after 30% and 80% 
confluence. MSC cultured at 30% confluence yielded a significantly higher number of 
maximum passages (p<0.05) than those cultured at high density (Fig. 2). Average 
culture senescence began at passage 10±7. Additionally, the cells cultured at low 
density also exhibited a significantly higher rate of population doubling (Fig. 3). 
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Figure 2: Mean maximum number of passages at 30% and 80% confluence  
(* indicates significance) 
MSC cultured at 30% confluence yielded a significantly higher number of maximum 
passages than those cultured at high density. 
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Figure 3: Mean duration of proliferation at 30% and 80% confluence 
(* indicates significance) 
Cells cultured at low density exhibited a significantly higher rate of population 
doubling. 
 
4.1.2  Colony forming unit-fibroblast (CFU-F) assay 
On day 14 following initial isolation and plating, the cells were stained using a Diff-
Quick  staining  set. The  resulting  CFU-F  exhibited  morphology  consistent  with  the 
expression of MSC, including typical homogeneous colony formation and individual 
fusiform cells (Fig. 4). The 5 cultures of cells obtained from the proximal extremity of 
the tibia, greater trochanter and vertebral body did not proliferate sufficiently enough 
to be included for further trials. 
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Figure 4: CFU-F  
(a) culture flasks and initial cell densities (b) colony at x80 magnification  (c) at x200 
magnification 
0,5 X 10
6  1 X 10
6  2 X 10
6   25 
4.1.3   Confirmation of MSC phenotype 
Phenotypical analysis of the cultures was performed using fluorescent activated cell 
sorting (FACS). All analyzed MSC samples expressed the surface antigens CD 71, 
CD73,  CD90  and  CD105  but  did  not  express  CD34  and  CD45  (Fig.  5).  This  is 
consistent with the characterization of MSC. Control samples could be successfully 
differentiated to an osteogenic phenotype. 
 
 
   
 
   
 
   
 
   
 
   
 
   
 
Figure 5: Representative FACS analysis of MSC 
(a) CD34- (b) CD45- (c) CD71+ (d) CD73+ (e) CD90+ (f) CD105+. Black signifies 
control isotype, red signifies antibody 
(a) CD34  (b) CD45 
(c) CD71  (d) CD73 
(e) CD90  (f) CD105   26 
4.1.4  Staining for osteogenic differentiation 
For verification of osteogenic differentiation, cells were stained following 14 days of 
supplemental  incubation  with  dexamethasone,  ascorbic  acid,  and  β-
glycerolphosphate. The von Kossa and alizarin stains quantified calcium deposition 
while  alkaline  phosphatase  (ALP)  expression  confirmed osteoblastic  differentiation 
(Fig. 6). 
a   
b   
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Figure 6: MSC staining for osteogenic differentiation  
(a) Von Kossa (b) alizarin red (c) alkaline phosphatase (arrows indicate calcium 
deposition in a and b and alkaline phosphatase activity in c)   27 
4.2  Evaluation of mean colony number 
 
4.2.1  Mean colony number: females 
The multiple trauma group demonstrated the highest mean colony number overall, 
with significant differences compared to the atrophic nonunion and control groups. 
Interestingly, the control group showed a significantly higher mean colony number 
than the atrophic nonunion group (p<0.05). The lowest mean colony number was 
found in the atrophic nonunion group (Fig. 7). 
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Figure 7: Mean colony number: females 
(* indicates significance vs. atrophic nonunion group; # indicates significance vs. 
control group) 
Total number of female patients n=18, control group n=4, single fracture n=3, multiple 
trauma n=4, atrophic nonunion n=5 
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4.2.2  Mean colony number: males 
In  the  male  groups,  significant  differences  (p<0.05)  were  found  in  all  subgroups. 
Again, the highest mean colony number overall was demonstrated in the multiple 
trauma group, with a significantly higher mean colony number compared to the single 
fracture and atrophic nonunion groups. As with females, a significantly higher mean 
colony  number  was  found  in  the  male  control  group  compared  to  the  atrophic 
nonunion as well as the single fracture groups. The lowest mean colony numbers 
were found in the atrophic nonunion and single fracture group (Fig. 8). 
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Figure 8: Mean colony number: males 
(* indicates significance vs. atrophic nonunion group; # indicates significance vs. 
single fracture group) 
Total number of male patients n=35, control group n=3, single fracture n=11, multiple 
trauma n=9, atrophic nonunion n=14 
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4.3  Evaluation of mean colony area 
 
4.3.1  Mean colony area: females 
Although the groups with the lowest mean colony area were found in the atrophic 
nonunion and single fracture groups, the differences were not significant (Fig. 9). 
 
0
2
4
6
8
10
12
14
16
control single fracture multiple trauma atrophic
nonunion
m
e
a
n
 
c
o
l
o
n
y
 
a
r
e
a
 
[
m
m
²
]
 
Figure 9: Mean colony area: females 
Total number of female patients n=18, control group n=4, single fracture n=3, multiple 
trauma n=4, atrophic nonunion n=5 
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4.3.2  Mean colony area: males 
Two groups demonstrated significantly higher mean colony areas (p<0.05): the 
multiple trauma compared to the single fracture group and the control compared to 
the single fracture group (Fig. 10). 
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Figure 10: Mean colony area: males 
(* indicates significance vs. single fracture group) 
Total number of male patients n=35, control group n=3, single fracture n=11, multiple 
trauma n=9, atrophic nonunion n=14 
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4.4  Evaluation of proliferative capacity 
 
4.4.1  Proliferative capacity: females 
Although  the  multiple  trauma  group  demonstrated  the  highest,  and  the  atrophic 
nonunion  and  control  groups  the  lowest  mean  cell  number  /  FOV,  no  significant 
differences were found regarding the female proliferative capacity groups (Fig. 11). 
 
0
10
20
30
40
50
60
control single fracture multiple trauma atrophic
nonunion
m
e
a
n
 
c
e
l
l
 
n
u
m
b
e
r
 
/
 
F
O
V
 
 
Figure 11: Proliferative capacity: females 
Values are based on the established significant correlation between cell density and 
corresponding gray level, determined by using the optical CFU-F density values. 
total number of female patients n=18, control group n=4, single fracture n=3, multiple 
trauma n=4, atrophic nonunion n=5 
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4.4.2  Proliferative capacity: males 
The highest proliferative capacity was demonstrated in the multiple trauma group, 
with significance (p<0.05) compared to the single fracture group (Fig. 12). 
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Figure 12: Proliferative capacity: males 
(* indicates significance vs. single fracture) 
Values are based on the established significant correlation between cell density and 
corresponding gray level, determined by using the optical CFU-F density values. 
total number of male patients n=35, control group n=3, single fracture n=11, multiple 
trauma n=9, atrophic nonunion n=14 
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4.5  Evaluation of gender 
 
4.5.1  Evaluation of gender: mean colony number 
The male group demonstrated a significantly higher mean colony number (p<0.05) 
compared to the female group in healthy volunteers (Fig. 13). 
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Figure 13: Influence of gender: mean colony number 
(* indicates significance) 
Total number of female patients n=18, total number of male patients n=35 
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4.5.2  Evaluation of gender: mean colony area 
Although the mean colony area was higher in the male group, the difference was not 
significant (Fig. 14). 
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Figure 14: Influence of gender: mean colony area 
Total number of female patients n=18, total number of male patients n=35 
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4.5.3  Evaluation of gender: proliferative capacity 
Although the mean cell number / FOV was higher in the male group, the difference 
was not significant (Fig. 15). 
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Figure 15: Influence of gender: proliferative capacity 
Total number of female patients n=18, total number of male patients n=35 
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4.6  Evaluation of age 
Single fracture and control groups were chosen to assess the influence of age on 
MSC  reservoir  and  proliferative  capacity  to  eliminate  unrelated  factors  such  as 
dysfunctions in wound healing or excessive injury found in atrophic nonunion and 
multiple trauma situations. Colony number (Fig. 16) decreased significantly (p<0.02) 
in patients over 40 years of age, whereas the proliferative capacity demonstrated 
only a tendency (p<0.09) towards decreasing values in older patients (Fig. 17). 
 
0
5
10
15
20
25
30
<40 years >40 years
age
m
e
a
n
 
c
o
l
o
n
y
 
n
u
m
b
e
r
 
 
Figure 16: Influence of age in single fracture and control groups: colony number 
Total number of patients <40 years of age n=7; total number of patients >40 years of 
age n=7 
(* indicates significance) 
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Figure  16:  Influence  of  age  in  single  fracture  and  control  groups:  proliferative 
capacity 
Total number of patients <40 years of age n=7; total number of patients >40 years of 
age n=7 
 
4.7  Evaluation of patient serum 
No significant correlations were observed between the number of CFU-F and the 
serum levels of estradiol, prolactin or IL-6. The serum concentration of testosterone 
was significantly elevated in male participants compared to female participants 
(440±250 versus 48±41, p<0.05). 
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5  Discussion 
This study clearly demonstrates the effect of injury pattern (single fracture, multiple 
trauma,  atrophic  nonunion)  on  the  reservoir  and  proliferative  capacity  of  MSC  in 
human bone marrow. To date, the influence of injury pattern and severity on MSC 
frequency has not been described. Further donor characteristics such as age and 
gender were also shown to influence MSC number and proliferation, as in previous 
studies (Muschler et al. 2001; Phinney et al. 1999). While current literature supports 
the general influence of physiological status, age and gender, a diversity of donor 
characteristic-related outcomes can be found. 
 
5.1  Characterization of MSC 
An  important  attribute  of  MSC  is  their  rapid  in  vitro  expansion.  Detailed  culture 
conditions  which  promote  the  most  efficient  expansion  however,  have  yet  to  be 
established. In the additional, parallel trial to optimize the MSC yield, cultures plated 
at low density generated more proliferative passages. A higher CFU-F frequency was 
observed  at  30%  than  at  80%  confluence.  Additionally,  the  cells  cultured  at  low 
density  exhibited  a  higher  rate  of  population  doubling.  Sotiropoulou  et  al.  (2006) 
evaluated multiple culture conditions for characterization of optimal parameters for 
large  clinical  scale  MSC  production  and  confirmed  that  the  MSC  plating  and 
passaging density are sensitive to the community effect in their microenvironment. In 
this regard, various components of the cultivation process can be examined. Similar 
investigations, although measuring only initial seeding density, report diverse findings. 
Colter et al. (2000) documented accelerated cell growth when plated at low density 
and suggested that this behavior could be explained by either cell-to-cell contact or 
factors that cells secrete into the medium. Conversely, other authors have found no 
significant effect on MSC proliferation but greater mineral deposit at higher densities 
(Jaiswal et al. 1997) or an increased osteoprogenitor (murine) cell proliferation at 
high initial cell densities (Purpura et al. 2004). 
Despite  the  variant  outcomes,  fundamental  advances  have  provided  useful 
information for effective MSC expansion. Bruder et al. (1997a), while passaging cells 
at 80-90% confluence, established the decline in cell proliferation as a function of 
increasing passage number. Culture senescence occurred between passages 10-15. 
As in other investigations (Banfi et al. 2000; Mendes et al. 2004), this observation 
was also supported in our study in which the average culture senescence began at   39 
passage 10±7, depending on the donor. Moreover, passage at 30% confluence is 
expectedly more effective for maximal cell expansion by limiting differentiation, as 
increasing  MSC  density  is  known  to  trigger  differentiation  (Caplan  et  al.  1983). 
Furthermore, cell proximity is not only important between individual MSC. Cell-to-cell 
contact between MSC and other cell types (cardiomyocytes, smooth muscle cells, 
endothelial  cells)  has  been  shown  to  induce  MSC  differentiation  into  those 
phenotypes (Rangappa et al. 2003; Ball et al. 2004; Wang et al. 2006). It is evident 
however, that further observations are necessary in order to maximize the efficiency 
of MSC expansion in large numbers. 
 
The CFU-F assay has become a standard in vitro assay for MSC concentration in 
bone marrow, providing a reliable quantitative measure for the occurrence of cells 
(Castro-Malaspina et al. 1980; Perkins & Fleischman 1990). The frequency of CFU-F 
can  be  used  as  a  surrogate  marker  for  MSC  frequency  (Wexler  et  al.  2003). 
Proliferative potential of the CFU-F can be further quantified by the mean cell density 
within a cell colony. Following assessment of the cell number per FOV (cell density) 
and  corresponding  gray  level,  we  demonstrated  that  the  optical  CFU-F  density 
correlates with the number of cells within a colony. The value for cell density in turn 
most likely reflects the true proliferative capacity, thus facilitating the evaluation and 
comparison of donor colonies. 
 
To  eliminate  complications  due  to  heterogeneous  cultures,  FACS  analysis  was 
performed and confirmed mesenchymal cell phenotype. Although no monospecific 
and  unique  marker  to  unequivocally  identify  MSC  has  been  ascertained,  various 
markers have been identified which facilitate isolation. Early surface markers were 
identified including STRO-1 (Simmons & Torok-Storb 1991) and endoglin, or CD105 
(Barry  et  al.  1999).  After  prolonged  investigation,  numerous  markers  have  been 
identified to verify or negate mesenchymal origin: MSC express CD29 (β1-integrin), 
CD73 (endonucleotidase), CD117, which is the receptor for the stem cell factor ckit 
(Haynesworth  et  al.  1992;  Pittenger  et  al.  1999),  CD  70,  CD90  and  HLA  class  I 
antigens but do not express typical hematopoietic markers such as CD34 and CD45 
or HLA class II antigens (Bruder et al. 1997b; Campagnoli et al. 2001; DeUgarte et 
al. 2003; Fibbe & Noort 2003; Risbud et al. 2006). CD271, also known as low-affinity 
nerve growth factor receptor (LNGFR), has been shown to be an efficient marker to   40 
isolate MSC from bone marrow (Quirici et al. 2002; Jones et al. 2006). To facilitate 
the analysis and comparison of MSC research, the Mesenchymal and Tissue Stem 
Cell Committee proposed the following surface markers for their definition of MSC: 
cells must express CD73, CD90 and CD105 lack expression of CD11b, CD14, CD 
19, CD34, CD79α and HLA-DR. As research in this area progresses quickly, there 
may  be  subsequent  changes  in  definition.  Our  analyses  however,  confirmed  the 
expression of a large selection of the above suggested markers. 
 
Plasticity, a further criterion of the Mesenchymal and Tissue Stem Cell Committee, 
describes the multipotent capacity of MSC to differentiate into other cell types. This 
was assessed through induction of osteogenic differentiation by supplementing the 
culture medium with dexamethasone, ascorbic acid and β-glycerophosphate. These 
supplements  have  been  extensively  reported  to  induce  and  enhance  osteogenic 
lineage differentiation from precursor cells (Jaiswal et al. 1997; Bruder et al. 1998b; 
Mendes  et  al.  2004).  Alkaline  phosphatase  (ALP)  expression  verified  osteoblastic 
differentiation.  The  significant  use  of  ALP  in  MSC  characterization  was  described 
almost 10 years ago (Jaiswal et al. 1997; D'Ippolito et al. 1999) and is now the most 
widely recognized marker for osteoblastic activity (Majumdar et al. 2000; Mendes et 
al. 2004). In addition, calcium deposition was confirmed and quantified by von Kossa 
and alizarin red staining, as in many previous investigations (Bianco et al. 2001a; 
Ciapetti et al. 2006). 
 
5.2  The influence of injury pattern and donor characteristics on MSC 
These  analyses  demonstrated  several  significant  trauma-related  modifications  in 
MSC reservoir and proliferation, in both male and female patients. Injury severity has 
a substantial effect on MSC colony number (reservoir). In multiple trauma patients, 
the highest CFU-F frequency of MSC was found, independent of gender and age. 
Proliferative capacity was also highest in multiple trauma patients, although data for 
female  patients  provided  insufficient  significance.  Furthermore,  in  the  case  of 
atrophic nonunion, the lowest CFU-frequency was detected, independent of gender. 
 
The stimulated reservoir and proliferative capacity in patients with multiple trauma 
can be explained by a higher skeletal cell turnover necessary for bone remodeling 
and  suggests  a  systemically-increased  osteogenic  potential  through  enhanced   41 
differentiation,  recruitment  and  migration  of  MSC.  Numerous  studies  support  the 
influence of injury on such osteogenic processes. In patients with both head injury 
and limb fracture there is evidence of an increased concentration of osteoblastic cells 
in  serum  (Bidner  et  al.  1990)  as  well  as  more  rapid  bone  union  and  enhanced 
fracture healing (Spencer 1987; Giannoudis et al. 2006), compared to limb fracture 
only. In the later 2 studies heterotopic bone formation was detected in those patients 
with  twofold  injuries  as  well,  giving  rise  to  questions  concerning  the  mechanism 
involved in the accelerated healing: injury severity or heterotopic bone formation. It is 
evident that central nervous system injury is frequently associated with heterotopic 
ossification (HO) and enhanced fracture healing (Andermahr et al. 2006; da Paz et 
al. 2007). Although it remains incompletely understood if it is truly enhanced healing 
or a form of heterotopic ossification, an increased osteoprogenitor activity is apparent 
(Balboni et al. 2006). 
In  severe  trauma  other  types  of  progenitor  cells  are  also  activated,  such  as 
hematopoietic  bone  marrow  cells  in  spinal  trauma  (Chernykh  et  al.  2006)  and 
endothelial progenitor cells in acute lung injury (Burnham & Moss 2006). Additionally, 
enhanced concentrations of the mediators VEGF and TGF-β in serum derived from 
multiple  trauma  patients  promote  the  differentiation  of  endothelial  progenitor  cells 
(Henrich et al. 2004). Serum-mediated changes in osteogenic processes can also be 
observed in severe trauma. Klein et al. (1999) detected an increased ALP activity in 
murine MSC following head injury. In a recent study of serum from polytraumatized 
patients,  MSC  stimulation  and  inhibition  of  osteoprogenitor  apoptosis  provided 
evidence of enhanced osteogenesis (Eid et al. 2006). Not surprisingly, enhancement 
of  MSC  is  not  limited  to  trauma  patients,  but  is  evident  in  complex  regenerative 
processes as well. Mansilla et al. (2006) documented significantly higher quantities of 
circulating MSC in patients during acute burn situations, and the percentage of MSC 
correlated with the size and severity of the burn. The summation of these results 
present a model in which, in response to severe injury, increased differentiation and 
recruitment  of  MSC  and  other  progenitor  cells  are  induced,  supplemented  by 
elevated  concentrations  of  various  mediators  which  further  promote  osteogenic 
processes and ultimately osseous tissue healing. 
 
While the extensive influence of injury severity on MSC is apparent, one of the many 
biochemical  mediators  involved,  cytokines,  must  be  considered  concurrently.   42 
Cytokines are a group of endogenous, pleiotropic proteins which have an essential 
function  in  immune  response  and  are  released  by  many  different  cells  relatively 
rapidly  after  injury  (Lin  et  al.  2000;  Keel  &  Trentz  2005).  There  is  evidence  that 
excessive  amounts  of  proinflammatory  mediators  have  a  detrimental  effect  on 
progenitor cells (Henrich et al. 2006). To evaluate the systemic inflammation, serum 
concentrations of the cytokine IL-6 were assessed. Contrary to expected results, no 
correlation with the CFU-F frequency or cell density was found. The increase in IL-6 
following severe trauma has been reported by many investigators (Klein et al. 1999; 
Fonseca et al. 2005; Keel & Trentz 2005; Lin et al. 2000) and a further correlation 
between  the  concentration  of  IL-6  and  injury  severity  has  also  been  established 
(Gebhard et al. 2000; Strecker et al. 2003). Fonseca et al. (2005) documented the 
dose- and time-dependent stimulating effect of epinephrine and norepinephrine on 
bone  marrow  cell  release  of  IL-6  and  suggested  a  correlation  with  the  persistent 
catecholamine  elevation  seen  following  severe  injury.  This  trauma-induced 
hypercatecholamine effect on MSC was not analyzed in this study but an interesting 
premise for further studies. These diverse findings confirm the extended involvement 
of  IL-6  in  the  trauma  situation  but  its  effect  on  MSC  necessitates  future 
investigations. 
 
Nonunions present an unfortunate outcome of trauma, where a fracture fails to unite 
within  6  months  (depending  on  the  definition).  The  etiology  is  multifactorial,  the 
incidence  varies  by  fracture  site  and  they  are  often  treated  by  autologous  bone 
marrow  grafting  (Babhulkar et al. 2005;  Hernigou  et al. 2006). In  this  regard,  the 
processes in bone marrow involved in bone healing and bone union are therefore of 
great interest in orthopedic surgery. In patients with atrophic nonunions, the MSC 
reservoir was significantly decreased, independent of gender. Additionally, there was 
no compensatory increase detected in the proliferative capacity of those patients. 
Similar  results  were  found  in  patients  with  single  fractures;  MSC  reservoir  was 
decreased with no compensatory increase in proliferation. It is interesting to note that 
in  patients  with  multiple  trauma,  both  reservoir  and  proliferative  capacity  were 
elevated. It appears that in the case of local bone injury, the absence of systemic 
stimulation present  in  multiple  trauma  results  in  reduced  activation  of  proliferative 
capacity. Due to the paucity of studies on MSC and atrophic nonunions, it is difficult 
to  compare  the  results  of  this  investigation  with  others.  In  an  interesting  recent   43 
examination of percutaneous autologous grafting for tibial atrophic nonunions, the 
concentration  and  number  of  CFU-F  from  the  bone  marrow-derived  cells  were 
evaluated (Hernigou et al. 2005). CFU-F was decreased in unsuccessful bone unions 
and  negatively  associated  with  longer  time  necessary  for  bone  union.  Moreover, 
CFU-F was increased in transplants in which the volume of mineralized callus was 
also  increased.  They  concluded  that  the  addition  of  bone  marrow-derived  cells 
enhances bone healing. The negative outcome observed in unsuccessful bone union 
confirms our findings. It appears that the reservoir of progenitor cells in bone marrow 
exert a stimulating effect on bone union processes. 
 
It  is  well  known  that  age  and  gender  effect  bone  growth,  development  and 
regeneration.  A  remodeling  balance  between  bone  formation  through  osteoblasts 
and resorption through osteoclasts is necessary to maintain bone mass. As skeletal 
maturation is reached around the age of 30, the dynamics shift toward resorption and 
bone mass gradually declines (Parfitt et al. 2000; Adachi & Takayanagi 2006), which 
can result in age-related fractures, osteopenia or osteoporosis (Raisz 2005; Russell 
et al. 2006). However, the exact function of MSC in these processes as well as in the 
trauma setting has yet to be elucidated. In this study, CFU-F occurrence in trauma 
patients is clearly both age- and gender-dependent. Colony number and proliferative 
capacity  declined  significantly  with  increasing  patient  age.  In  a  review  of  the 
literature, there are vast discrepancies. Some authors describe a decline in CFU-F 
occurrence (D’Ippolito et al. 1999; Nishida et al. 1999; Muschler et al. 2001) while 
others have found additional decreasing ALP expression (Quarto et al. 1995; Baxter 
et al. 2004) or osteoblastic differentiation (Abdallah et al. 2006) with increasing age. 
Oreffo  et  al.  (1998)  evaluated  MSC  changes  in  patients  with  osteoarthritis  and 
reported  no  decrease  in  colony  frequency  but  a  decrease  in  colony  size  in  older 
patients,  which  implies  a  loss  of  proliferation.  Alternatively,  other  evaluations 
provided  no  correlation  between  MSC  growth  (Phinney  et  al.  1999)  and  age.  In 
further studies including patients with osteoporosis (Stenderup et al. 2001; Justensen 
et al. 2002), no significant differences were detected in MSC colony number, cell 
density and mineralized matrix formation in young, old or patients with osteoporosis.  
An  elegant  method  of  evaluating  the  aging  process  in  MSC  is  determining  the 
telomere length. Telomeres are specialized regions of highly repetitive DNA at the 
end of eukaryotic chromosomes which participate in cell replication. Their shortening   44 
is involved in the cellular aging process (Blackburn 2005) and their fragment length is 
used to analyze, in this case, MSC replicative potential and lifespan. For instance, 
Parsch et al. (2004) found in their study comparing MSC with chondrocytes that the 
telomere length of MSC was not related to the age of the donor. But MSC appear to 
age  themselves  as  soon  as  they  begin  expanding  (Bonab  et  al.  2006).  Another 
recent  publication  described  not  only  a  loss  of  proliferative  and  differentiation 
capacity, a slower growth rate and a lower number of total population doublings (PD) 
with increasing donor age, but demonstrated that even minimal in vitro expansion (10 
PD)  induces  rapid  losses  of  MSC  replicative  lifespan  (Baxter  et  al.  2004).  It  is 
possible that the MSC frequency in bone marrow is maintained with age, but the cells 
lack the capabilities to form sufficient colonies. 
 
In consideration of these diverse findings, it still remains to be determined if age has 
an effect on MSC concentration in bone marrow. Many findings, including ours, are 
consistent with an age-dependent depletion in osteoprogenitor cells in bone marrow 
and their decreased proliferation potential, which possibly contribute to reduced bone 
mass and repair. It is feasible to assert that the age-dependent changes discussed 
above are a result of gender difference, as estrogen is known to have a critical role in 
bone loss (Raisz 2005). In a comparison of MSC donor properties, Phinney et al. 
(1999) presented no correlation between MSC growth rate and gender, in contrast to 
results  confirming  a  decrease  in  CFU-F  in  women  (Muschler  et  al.  2001)  and 
postmenopausal loss of bone mass (Brockstedt et al. 1993). We found that the MSC 
reservoir in male patients was indeed significantly higher than in female, but analyses 
of estradiol levels, the primary estrogen in men and women, resulted in no significant 
differences. Moreover, the MSC frequency increased in female patients with multiple 
trauma in comparison to that of males, which can be explained by the effects of injury 
severity discussed above. 
Nevertheless,  age-  and  gender-associated  aspects  of  the  results  suggest  a 
dependence  on  sex  hormones or  other  biochemical  mediators. Receptors for  sex 
hormones  such  as  testosterone  and  estrogen  mediate  their  interactions  with 
osteoblast  and  osteoclast  precursors  in  bone  formation  and  resorption  processes 
(Michael et al. 2005). Changes in the levels of such sex hormones can in turn result 
in pathological changes in bone remodeling (Lee K et al. 2003; Raisz 2005). The 
regulatory  actions  of  estrogen  on  osteoprogenitor  cells  have  been  reported  to   45 
promote their phenotypic expression in the form of increased ALP expression (Holzer 
et  al.  2002),  improved  calcium  deposition  (Hong  et  al.  2006)  and  increased 
proliferation (DiSilvio et al. 2006). Prolactin, a hormone synthesized in the pituitary 
gland  and  ectopically,  regulates  milk  production  in  the  mammary  gland,  lipid 
metabolism, insulin secretion stimulation and citrate production in the prostate (Ben-
Jonathan  et  al.  2006).  It  has  been  shown  to  influence  bone  mass  formation  and 
maintenance (Freemark et al. 1997; Clement-Lacroix et al. 1999), MSC differentiation 
(Ogueta et al. 2002) and improve osteogenesis with heterotopic ossification in severe 
head injury (Wildburger et al. 1998). Testosterone, the primary androgen in men and 
women  inhibits  osteoclasts  activity  and  bone  resorption  (Hofbauer  et  al.  2002; 
Michael  et  al.  2005).  Therefore,  in  addition  to  the  estradiol  and  IL-6  analyses 
described  above,  prolactin  and  testosterone  values  were  evaluated  as  well  but 
yielded  no  correlations  with  MSC  occurrence.  The  testosterone  levels  were,  not 
surprisingly, significantly elevated in male patients. It is important to note however, 
that estrogen, more than testosterone, regulates bone resorption in both men and 
women (Hofbauer et al. 2002; Van Pottelbergh et al. 2004). In summation, age and 
gender account for only a fraction of variability; Thus, MSC can be obtained from 
patients of both genders and all ages, provided methods for stimulating proliferation 
are further identified and implemented. 
 
In addition to injury severity, age, gender and hormones, various methods of isolation 
and cultivation have been found to influence MSC. The source of MSC for instance 
has been the subject of considerable examination. The use of cells of different origin 
such as cancellous bone fragments (Noth et al. 2002; Bertram et al. 2005), femoral 
bone marrow (Lee HS et al. 2003), lumbar vertebral body (Risbud et al. 2006) and 
umbilical cord and peripheral blood (Wexler et al. 2003) pose difficulties in comparing 
outcomes. Bone marrow aspirates from the iliac crest are currently the standard site 
of  isolation.  In  our  study,  MSC  isolated  from  the  proximal  extremity  of  the  tibia, 
greater trochanter and vertebral body did not proliferate sufficiently, supporting the 
use  of  the  iliac  crest  for  efficient  expansion  of  MSC.  Other  investigators  have 
examined  novel  methods  of  optimizing  expansion.  Since  medium  containing  fetal 
bovine  serum  (FBS)  can  cause  immune  reactions  or  transmit  bovine  diseases, 
autologous  serum  is  a  viable,  less  expensive  alternative.  It  was  shown  to  be  as 
effective in stimulating MSC growth as FBS, more effective in promoting cell motility   46 
(Kobayashi et al. 2005) and maintain differentiation potential (Yamamoto et al. 2003; 
Stute et al. 2004). 
These diverse methods of isolation and cultivation contribute to the discrepancies 
which  arise  in  the  abundant  publications  available.  Harvest  site,  donor  variability, 
nonstandardized  assessment  of  various  parameters  and  general  dissimilar 
experimental  conditions  are  potential  sources  for  limitations  in  analyses. 
Establishment of uniform approaches for MSC cultivation is therefore essential for 
future research. 
 
5.3  Conclusion 
The frequency and proliferative capacity of MSC in trauma patients are regulated by 
the interactions of an extensive spectrum of various factors. In multiple trauma, yet 
unidentified  processes  in  bone  marrow  and  serum  induce  the  release  of  factors 
which stimulate the reservoir and proliferation of MSC. Furthermore, in the case of 
atrophic  nonunion,  the  MSC  concentration  in  bone  marrow  is  depleted  and  the 
absence  of  systemic  stimulation  present  in  multiple  trauma  results  in  reduced 
activation  of  proliferative  capacity.  Such  patients,  with  severe  injury  or  atrophic 
nonunion, present clinically higher necessities for a cell therapy - multiple trauma 
patients due to their extensive injuries, encompassing often multiple and medically 
challenging fractures, and atrophic nonunion patients due to their insufficient MSC 
resources.  Future  research  is  therefore  essential  to  identify  further  factors  which 
regulate  MSC  activity  in  trauma  and  nonunion  situations.  Moreover,  in  order  to 
enhance MSC number and proliferative capacity for therapeutic applications in these 
cases, development of methods to stimulate such factors is necessary. Overall, MSC 
are  a  viable  cellular  resource  for  a  multitude  of  therapies  including  degenerative 
diseases,  congenital  deformities,  trauma-related  wound  management  and  acute 
injury. They present an exciting source of cells for future regeneration and restoration 
of musculoskeletal tissues damaged by disease or trauma. 
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6  Summary 
 
Mesenchymal stem cells (MSC), also referred to as marrow stromal cells, maintain 
the capacity to differentiate into multiple mesenchymal lineages such as osteoblasts, 
chondrocytes, adipocytes, myoblasts, stromal, neural and endothelial cells. The use 
of  autologous  MSC  has  generated  widespread  interest  due  to  their  developing 
application in regenerative medicine and tissue engineering in orthopedic surgery. 
They have become an indispensable cell source for successful implementation in 
many  bone  reconstruction  procedures.  In  addition  to  their  multipotency  and  self-
renewal  capacity,  they  are  easily  harvested,  have  demonstrated  a  homing 
mechanism and can be efficiently expanded in vitro, thus providing a safe and cost-
efficient tissue replacement for patients with skeletal injury or disease. 
Little  information  is  currently  available  concerning  donor  characteristics  for  tissue 
engineering growth of osseous tissue. This study examines the influences of such 
donor characteristics, including injury pattern, gender, age, and site of harvest on the 
quantity,  quality  and  osteogenic  differentiation  of  MSC.  The  goal  is  to  evaluate 
whether certain patient groups are practically suitable for an ex vivo expansion and 
therapeutic reimplantation of MSC. 
The  effect  of  injury  pattern  on  the  reservoir  and  proliferative  capacity  of  MSC  in 
human bone marrow is clearly demonstrated in this analysis. Age and gender were 
also shown to influence MSC number and proliferation, as in previous studies. 
A total of 53 participants (46 patients and 7 healthy volunteers ranging from 18 to 64 
years of age), who were scheduled to undergo operative procedures on the pelvis, 
vertebrae,  tibia  or hip  as  well  as  cancellous  bone autografts for  reconstruction  of 
various bone defects, were included in the study. Participants were divided into 4 
groups  for  each  gender:  single  fracture,  multiple  trauma,  atrophic  nonunion  and 
healthy  volunteers.  A  minimum  of  6  ml  bone  marrow  samples  were  aspirated 
intraoperatively  and  processed  immediately  according  to  protocol.  Following 
cultivation  and  expansion for  14  days,  the  cells  were  then  stained for  the  colony 
forming  unit-fibroblast  (CFU-F)  assay  and  each  culture  flask  was  photographed, 
digitized and converted to an 8 bit grey level TIF-format. Using the digitized CFU-F 
assay,  the  mean  colony  number,  mean  colony  area  and  mean  cell  number  per 
microscopic field of view (cell density) could be determined. In addition, confirmation 
of MSC phenotype was established using fluorescent activated cell sorting (FACS).   48 
MSC potential for osteogenic differentiation was quantified by von Kossa, alkaline 
phosphatase and alizarin staining. Furthermore, serum from a total of 39 randomly 
chosen  participants  was  collected  and  tested for  hormone  levels  of  17β-estradiol, 
testosterone and prolactin as well as the cytokine interleukin-6. 
These analyses demonstrate several significant trauma-related modifications in MSC 
reservoir  and  proliferation,  in  both  male  and  female  patients.  In  multiple  trauma 
patients, the highest MSC frequency was found, independent of gender and age. 
Proliferative capacity was also highest in male multiple trauma patients. In the case 
of atrophic nonunion, the lowest MSC reservoir was detected, independent of gender. 
Furthermore, MSC frequency in male patients was significantly higher than in female, 
although analyses of hormone and interleukin-6 levels provided no correlation. Age-
related changes in MSC reservoir could also be observed, whereas the proliferative 
capacity produced only a tendency toward decreasing values with increasing age. 
Concerning the site of cell harvest, MSC isolated from the proximal extremity of the 
tibia, greater trochanter and vertebral body did not proliferate sufficiently enough to 
be included in statistical analysis, supporting the use of the iliac crest for efficient 
expansion of MSC. 
This data suggests the interaction of yet to be identified processes in bone marrow in 
multiple trauma situations which stimulate the activation and mobilization of MSC. 
Moreover,  in  the  case  of atrophic  nonunion,  the  concentration  in bone  marrow  is 
depleted and the absence of systemic stimulation present in multiple trauma results 
in reduced activation of proliferative capacity. Such patients, with severe injury or 
atrophic nonunion, represent a group of patients with an especially acute necessity 
for effective and successful bone reconstruction. This data can be used to determine 
the applicability of MSC from various patient groups for osseous tissue replacement 
procedures. Especially in such medically challenging situations, further research is 
essential  not  only  to delineate  the factors  involved  in  MSC  regulation but also  to 
develop methods to stimulate MSC expansion and proliferation. 
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7  Zusammenfassung 
 
Mesenchymale  Stammzellen  (MSC),  auch  als  „marrow  stromal  cells“  bezeichnet, 
besitzen  die  Kapazität  zur  Differenzierung  in  unterschiedliche  Zellreihen  wie 
Osteoblasten, Chondrozyten, Adipozyten, Myoblasten, Stromazellen, neurale Zellen 
und  Endothellzellen.  Der  mögliche  klinische  Einsatz  autologer  MSC  für  die 
Gewebetechnik  (tissue  engineering)  im  Bereich  der  Wiederherstellungschirurgie, 
Traumatologie  und  Orthopädie  ist  mittlerweile  das  Thema  von  zahlreichen 
wissenschaftlichen und medizinischen Studien. Charakteristisch für MSC sind nicht 
nur  Multipotenz  und  die  Kapazität  zur  Selbsterneuerung,  sie  sind  auch  leicht 
isolierbar,  besitzen  einen  Homing-Mechanismus  und  können  effektiv  in  vitro 
expandiert werden. Dadurch stellen sie eine sichere und kosteneffiziente Option für 
Gewebsersatz für Patienten mit ossären Verletzungen oder Erkrankungen dar. 
Derzeit gibt es nur unzureichende Informationen bezüglich der Eigenschaften von 
MSC  in  Abhängigkeit  des  Spenders.  Diese  Arbeit  untersucht  den  Einfluss  von 
Spendereigenschaften wie Verletzungsmuster, Geschlecht, Alter und Entnahmestelle 
auf  die  Quantität,  Qualität  und  osteogene  Differenzierung  mesenchymaler 
Stammzellen.  Ziel  der  Evaluation  ist  Aufschluss  zu  geben,  ob  MSC  bestimmter 
Patientengruppen  überhaupt  für  eine  ex  vivo  Expansion  und  anschließende 
therapeutische Reimplantation geeignet sind. 
Der  signifikante  Einfluss  des  Verletzungsmusters  auf  das  Reservoir  und  die 
proliferative  Kapazität  von  MSC  im  menschlichen  Knochenmark  wird  in  dieser 
Analyse eindeutig nachgewiesen. Analog zu früheren Studien korrelierten Alter und 
Geschlecht mit der MSC-Konzentration und –Proliferation. 
Insgesamt 53 Personen (46 Patienten und 7 gesunde Freiwilligen im Alter von 18 bis 
64 Jahren) wurden in die Studie eingeschlossen. Die Knochenmarkpunktion erfolgte 
während einer ohnehin geplanten Operation an Beckenkamm, Wirbelsäule oder Tibia. 
Die  Teilnehmer  wurden  gemäß  ihres  Verletzungsmusters  in  4  Gruppen  eingeteilt: 
Monofraktur,  Polytrauma,  Pseudarthrose  und  Kontrolle.  Mindestens  6  ml 
Knochenmark wurden intraoperativ aspiriert und sofort nach einem Standardprotokoll 
verarbeitet. Nach 14 Tage Kultivation und Expansion wurden Zellen für den Colony 
Forming  Unit-Fibroblast  (CFU-F)-Test  gefärbt  und  anschließend  fotografiert, 
digitalisiert  und  in  8-Bit-Graustufen-TIF formatiert.  Anhand der  digitalisierten  CFU-
Assays  konnten  die  mittlere  Koloniezahl,  Koloniegröße  und  Zellzahl  pro  Kolonie   50 
bestimmt  werden.  Der  Phänotyp  der  kultivierten  MSC  wurde  mittels 
Durchflusszytometrie  bestätigt  und  das  Potential  zur  osteogenen  Differenzierung 
durch  von  Kossa-,  Alkalische  Phosphatase-  und  Alizarin-Färbung  überprüft. 
Weiterhin wurde in Serumproben von insgesamt 39 zufällig ausgewählte Patienten 
17β-Estradiol-, Testosteron-, Prolaktin und Interleukin-6 Spiegel bestimmt. 
Diese  Arbeit  zeigt  bei  Männer  und  Frauen  multiple,  signifikante, 
verletzungsbezogene  Modifizierungen  im  MSC  Reservoir  und  in  der  MSC-
Proliferation. Polytraumen zeigten die höchste MSC-Konzentration im Knochenmark, 
unabhängig vom Geschlecht oder Alter. Die proliferative Kapazität war am höchsten 
bei  männlichen  Patienten  mit  Polytrauma.  Bei  Pseudarthrose  konnte  unabhängig 
vom  Geschlecht  die  niedrigste  MSC-Konzentration  im  Knochenmark  festgestellt 
werden. Des Weiteren war die MSC Frequenz bei männlichen Patienten signifikant 
höher  als  bei  weiblichen  Patienten.  Die  Hormon-  bzw  der  Interlekin-6-Spiegel 
korrelierten  jedoch  nicht  mit  den  Stammzellparametern.  Altersabhängige 
Veränderungen  im  MSC  Reservoir  wurden  beobachtet,  wobei  die  proliferative 
Kapazität nur eine Tendenz zu verminderten Werten mit zunehmendem Alter aufwies. 
Untersuchungen  zum  Einfluss  der  Entnahmestelle  ergaben,  dass  MSC  aus  dem 
Tibiakopf oder Wirbelkörper nur ungenügend wachsen. Dieses Ergebnis unterstützt 
die Hypothese, dass hauptsächlich MSC aus dem Knochenmark des Beckenkamms 
zur effizienten MSC Expansion geeignet sind. 
Die Ergebnisse weisen auf noch unklare Prozesse im Knochenmark hin, welche bei 
Polytrauma die Aktivierung und Mobilisierung von MSC stimulieren. Weiterhin ist bei 
Pseudarthrose  die  MSC-Konzentration  im  Knochenmark  reduziert.  In  diesem  Fall 
bewirkt  wahrscheinlich  die  fehlende  systemische  Stimulation  eine  verminderte 
Aktivität.  Besonders  Patienten  mit  schweren  Verletzungen  oder  Pseudarthrose 
haben  höhere  Risiken  für  Knochenheilungsstörungen  und  benötigen  deshalb 
effektive und sichere Methoden zur Knochenrekonstruktion und gegebenenfalls für 
Knochenersatz. Für die zukünftige Verwendung von autologen ex vivo expandierten 
MSC  geben  diese  Erkenntnisse  Aufschluss,  bei  welchen  Patientengruppen  MSC 
eine  ausreichende  Qualität  für  eine  therapeutische  Anwendung  aufweisen. 
Besonders  für  problematische  Fälle  sind  weitere  Studien  notwendig,  um  die 
detaillierte  Regulation  von  MSC  zu  untersuchen  und  Kultivierungs-  und 
Expandierungsbedingungen zu verbessern.   51 
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9  List of abbreviations 
 
ALP: alkaline phosphatase 
CD: cluster of differentiation 
CFU-F: colony forming unit-fibroblast 
CMV: cytomegalovirus 
FACS: fluorescent activated cell sorting 
FBS: fetal bovine serum 
FOV: field of view 
HIV: human immune deficiency virus 
HLA: human leukocyte antigen 
HO: heterotopic ossification 
IL: interleukin 
ISS: injury severity score 
LNGFR: low-affinity nerve growth factor receptor 
MSC: marrow stromal cell, mesenchymal stem cell 
PBS: phosphate buffered saline 
PD: population doubling 
TGF-β: transforming growth factor beta 
TIFF: tagged image file format 
VEGF: vascular endothelial growth factor 
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10  Appendix 
 
Self preparation: 5% silver nitrate solution 
5 gram silver nitrate dissolved in 100 ml distilled water 
 
Self-preparation: 5% sodium thiosulfate solution 
5 gram thiosulfate dissolved in 100 ml distilled water 
 
Protocol 1: Isolation of MSC from bone marrow aspirate 
a)  wash cells (1:1 v/v) with PBS w/o Mg
2+ and Ca
2+ 
b)  centrifuge at 850 g for 10 minutes 
c)  aspirate the supernatant 
d)  repeat steps a) to c) 
e)  fill with PBS w/o to original volume from a) 
f)  fill a Falcon tube of Ficoll 1.073 g to original volume from a) 
g)  pipet the cells carefully onto the Ficoll 
h)  centrifuge at 1000 g for 30 minutes 
i)  transfer the opaque interface into a clean Falcon tube 
j)  add 30 ml PBS w/o containing FBS 2% to the cells 
k)  pellet cells by centrifugation at 850 g for 10 minutes 
l)  aspirate the supernatant 
m) resuspend the cells in 3 ml MesenCult Basal Medium for counting 
 
Protocol 2: Cell count 
a)  combine 150 µl erythrocyte lysis solution with 50 µl of the cell suspension, vortex 
b)  place in water bath at 37° C for 5 minutes 
c)  add 50 µl Türks dye, vortex 
d)  count cells using Neubauer counting chamber and adjust density for plating 
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Protocol 3: CFU-Assay 
a)  using cells from Protocol 1, plate cells in 3 culture flasks, at a density of 5 x 10
5, 1 
x 10
6 and 2 x 10
6 in 10 ml each of MesenCult Basal Medium 
b)  incubate cells for 14 days in humidified incubator at 37° C, 5% CO 2, changing 
medium 3 times per week 
c)  on day 14 remove medium and rinse cells with distilled water 
d)  fix cells with 1 ml/culture flask Diff-Quick formula 1 (methanol) for 5 seconds 
e)  stain cells with 1 ml/culture flask Diff-Quick formula 2 (buffered eosin) for 5 
seconds 
f)  stain cells with 1 ml/culture flask Diff-Quick formula 3 (buffered azure) for 5 
seconds 
g)  rinse cells thoroughly but gently with distilled water and allow to air-dry 
 
Protocol 4: Von Kossa staining 
a)  wash cells 3 times with distilled water 
b)  set the cells with 1 ml ice cold ethanol for 20 minutes (in freezer) 
c)  wash again 3 times with distilled water 
d)  incubate cells with 1 ml 5% silver nitrate solution for 1 hour (room temperature) 
e)  wash again 3 times with distilled water 
f)  remove un-reacted silver with 1 ml 5% sodium thiosulfate for 5 minutes 
g)  counterstain with 1 ml nuclear fast red for 10 min 
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